- Leap Therapeutics Inc ASCO GI 2024 DeFianCe Study Webcast TranscriptJan 23, 2024
- Leap Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- Leap Therapeutics Inc at Robert W Baird Global Healthcare Conference TranscriptSep 13, 2023
- Leap Therapeutics Inc at HC Wainwright Investment Conference - New York TranscriptSep 11, 2023
- Leap Therapeutics Inc Annual Shareholders Meeting TranscriptJun 16, 2023
- Leap Therapeutics Inc Acquires Flame Biosciences TranscriptJan 17, 2023
- Leap Therapeutics Inc at Piper Sandler Healthcare Conference TranscriptNov 29, 2022
- Leap Therapeutics Inc - R&D Day TranscriptJul 12, 2022
- Leap Therapeutics Inc ASCO GI 2022 DisTinGuish Study Conference Call TranscriptJan 21, 2022
- Leap Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2022
- Leap Therapeutics Inc ESMO 2021 DisTinGuish Study Conference Call TranscriptSep 17, 2021
- Leap Therapeutics Inc at Ladenburg Thalmann Virtual Healthcare Conference TranscriptJul 14, 2021
- Leap Therapeutics Inc at Raymond James Human Health Innovation Conference (Virtual) TranscriptJun 21, 2021
- Leap Therapeutics Inc DKN-01 Clinical Data Conference Call TranscriptMar 22, 2021
- Leap Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 14, 2021
- Leap Therapeutics Inc Annual Shareholders Meeting TranscriptJun 16, 2020
- Leap Therapeutics, Inc. - Special Call TranscriptApr 23, 2020
- Leap Therapeutics, Inc. - Special Call TranscriptAug 06, 2019
Leap Therapeutics Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript
Hello, everybody. So my name is Timur Ivannikov, and I am an analyst -- biotech analyst at Raymond James. Today, we are pleased to host Leap Therapeutics at our annual Human Health Innovation Conference.
So joining us for a fireside chat today is Leap Therapeutics' President and CEO, Doug Onsi; and CMO, Cyndi Sirard. Thank you very much, Doug and Cyndi, for joining us, and thanks to everyone as well.
So -- and to start off, Doug, maybe you could provide a brief overview of Leap Therapeutics, given we are approaching an important data catalyst in 3Q 2021 in gastroesophageal cancer.
Good afternoon, Timur. Thank you very much to you and Raymond James for inviting us to participate in the conference.
Leap Therapeutics is an oncology drug development company focused on developing our DKN-01 monoclonal antibody. And DKN-01 targets DKK1, which is a protein produced by cancer cells that modulates important cell signaling
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)